Athira Pharma (ATHA) to Release Earnings on Thursday

Athira Pharma (NASDAQ:ATHA) is expected to be releasing its earnings data on Thursday, February 20th. Analysts expect Athira Pharma to post earnings of ($0.45) per share for the quarter.

Athira Pharma Stock Down 5.3 %

Shares of Athira Pharma stock opened at $0.44 on Wednesday. The company has a market cap of $17.13 million, a PE ratio of -0.16 and a beta of 2.97. Athira Pharma has a 52 week low of $0.41 and a 52 week high of $4.30. The business has a 50 day moving average price of $0.54 and a 200-day moving average price of $0.94.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.